Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Payables: 2017-2025

Historic Payables for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $6.7 million.

  • Denali Therapeutics' Payables fell 29.70% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year decrease of 17.13%. This contributed to the annual value of $11.1 million for FY2024, which is 17.44% up from last year.
  • As of Q3 2025, Denali Therapeutics' Payables stood at $6.7 million, which was down 37.80% from $10.8 million recorded in Q2 2025.
  • Denali Therapeutics' 5-year Payables high stood at $13.9 million for Q2 2024, and its period low was $1.6 million during Q1 2021.
  • Its 3-year average for Payables is $10.0 million, with a median of $9.6 million in 2024.
  • Per our database at Business Quant, Denali Therapeutics' Payables surged by 346.22% in 2021 and then slumped by 41.62% in 2022.
  • Over the past 5 years, Denali Therapeutics' Payables (Quarterly) stood at $4.8 million in 2021, then slumped by 41.62% to $2.8 million in 2022, then spiked by 239.89% to $9.5 million in 2023, then increased by 17.44% to $11.1 million in 2024, then declined by 29.70% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $10.8 million for Q2 2025, and $8.5 million during Q1 2025.